Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
2 minute read

Immutep Tuesday, It Achieved 50% Enrollment Milestone in Randomised Phase IIb TACTI-003 Trial for First Line Head & Neck Cancer

By Charles Gross
Today, 2:38 PM
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that it has enrolled and randomised over 50% of the planned 154 patients in the TACTI-003 Phase IIb trial.

IMMP

Read More
3 minute read

Immutep Announced on Thursday, Successful Meeting With the FDA on Eftilagimod Alpha Plus Chemotherapy for the Treatment of Metastatic Breast Cancer

By Charles Gross
Today, 2:38 PM
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the results of a positive follow-up Type C meeting with the US Food and Drug Administration (FDA) regarding late-stage clinical development plans for its first-in-class soluble LAG-3 pr

IMMP

Read More
1 minute read

Immutep Announced New Patent Granteds in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination

By Charles Gross
Today, 2:38 PM
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, is pleased to announce the grant of two new patents (numbers 7160345 and 10- 2441425) entitled "Combined Preparations for the Treatment of Cancer" by the Japanese Patent Office and South Korean Patent Office, respectively

IMMP

Read More
2 minute read

Immutep Announced Independent Data Monitoring Committee Positive Recommendation to Continue TACTI-003 Trial as Planned

By Charles Gross
Today, 2:38 PM
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that the Independent Data Monitoring Committee (IDMC) for the randomised, controlled Phase IIb TACTI-003 trial has reviewed initial safety data and recommended continuing the trial with no modificatio

IMMP